ATE222489T1 - Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren - Google Patents
Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumorenInfo
- Publication number
- ATE222489T1 ATE222489T1 AT98955056T AT98955056T ATE222489T1 AT E222489 T1 ATE222489 T1 AT E222489T1 AT 98955056 T AT98955056 T AT 98955056T AT 98955056 T AT98955056 T AT 98955056T AT E222489 T1 ATE222489 T1 AT E222489T1
- Authority
- AT
- Austria
- Prior art keywords
- thyroxine
- malignant tumors
- ketone
- treatment
- significant hormonal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/956,711 US5922775A (en) | 1997-10-23 | 1997-10-23 | Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity |
| PCT/US1998/022383 WO1999020263A1 (en) | 1997-10-23 | 1998-10-23 | Thyroxine analogues having no significant hormonal activity to treat malignant tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE222489T1 true ATE222489T1 (de) | 2002-09-15 |
Family
ID=25498590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98955056T ATE222489T1 (de) | 1997-10-23 | 1998-10-23 | Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5922775A (de) |
| EP (1) | EP1024800B1 (de) |
| AT (1) | ATE222489T1 (de) |
| AU (1) | AU1195499A (de) |
| DE (1) | DE69807349T2 (de) |
| ES (1) | ES2181298T3 (de) |
| WO (1) | WO1999020263A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| JP2002507567A (ja) * | 1998-03-25 | 2002-03-12 | ラージ スケール バイオロジー コーポレイション | 血管形成を阻害するための安息香酸誘導体 |
| US6433012B1 (en) * | 1998-03-25 | 2002-08-13 | Large Scale Biology Corp. | Method for inhibiting inflammatory disease |
| US6326402B1 (en) | 1998-08-12 | 2001-12-04 | Octamer, Inc. | Methods for treating viral infections using a compound capable of inhibiting microtubules |
| US6677473B1 (en) | 1999-11-19 | 2004-01-13 | Corvas International Inc | Plasminogen activator inhibitor antagonists |
| US6638977B1 (en) | 1999-11-19 | 2003-10-28 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists |
| US6613534B2 (en) | 2001-03-20 | 2003-09-02 | Wake Forest University Health Sciences | MAP-2 as a determinant of metastatic potential |
| CN1882327A (zh) * | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| MX2007014502A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos para el tratamiento de enfermedades del higado graso. |
| WO2006128056A2 (en) * | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| ZA200800907B (en) * | 2005-07-18 | 2010-04-28 | Bipar Sciences Inc | Treatment of cancer |
| US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| JP2010504079A (ja) * | 2006-06-12 | 2010-02-12 | バイパー サイエンシズ，インコーポレイティド | Ｐａｒｐ阻害剤を用いる疾病の治療方法 |
| WO2008030892A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
| CN101534836B (zh) * | 2006-09-05 | 2011-09-28 | 彼帕科学公司 | Parp抑制剂在制备治疗肥胖症的药物中的用途 |
| WO2008030887A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing parp inhibitors and uses thereof |
| WO2008030883A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| CN101903025A (zh) * | 2007-10-19 | 2010-12-01 | 彼帕科学公司 | 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物 |
| US7732491B2 (en) | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| MX2010008572A (es) * | 2008-02-04 | 2010-11-30 | Bipar Sciences Inc | Metodos de diagnostico y tratamiento de enfermedades mediadas por poli(adp-ribosa) polimerasa. |
| WO2018022851A1 (en) | 2016-07-28 | 2018-02-01 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| RU2019114863A (ru) | 2016-11-02 | 2020-12-03 | Иммуноджен, Инк. | Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp |
| JP2020500199A (ja) | 2016-11-21 | 2020-01-09 | バイキング・セラピューティクス・インコーポレイテッド | グリコーゲン蓄積症の治療方法 |
| MX2019009200A (es) * | 2017-02-03 | 2019-10-21 | Univ California | Composiciones y métodos para inhibir el reticulón 4. |
| AU2018280118B2 (en) | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| US11433074B2 (en) | 2017-06-22 | 2022-09-06 | Triact Therapeutics, Inc. | Methods of treating glioblastoma |
| EP3687501A4 (de) | 2017-09-29 | 2021-06-23 | Triact Therapeutics, Inc. | Iniparib-formulierungen und verwendungen davon |
| WO2020039094A1 (en) * | 2018-08-24 | 2020-02-27 | Xeniopro GmbH | Phenoxy(hetero)aryl ethers of antiproliferative activity |
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2019195658A1 (en) | 2018-04-05 | 2019-10-10 | Dana-Farber Cancer Institute, Inc. | Sting levels as a biomarker for cancer immunotherapy |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US20220305048A1 (en) | 2019-08-26 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB642159A (en) * | 1947-10-23 | 1950-08-30 | Glaxo Lab Ltd | Improvements in or relating to the preparation of diphenyl ethers |
| GB643089A (en) * | 1947-10-23 | 1950-09-15 | Glaxo Lab Ltd | Improvements in or relating to the preparation of 2:6-dihalogeno diphenyl ethers |
| US4724234A (en) * | 1982-09-17 | 1988-02-09 | Therapeutical Systems Corp. | Method for producing oncolysis |
| US4816255A (en) * | 1985-07-31 | 1989-03-28 | Ghent William R | Treatment of iodine deficiency breast syndrome |
| GB9211415D0 (en) * | 1992-05-29 | 1992-07-15 | Ici Plc | Process for the production of purified terephthalic acid |
| US5736576A (en) * | 1996-06-04 | 1998-04-07 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
-
1997
- 1997-10-23 US US08/956,711 patent/US5922775A/en not_active Expired - Lifetime
-
1998
- 1998-10-23 EP EP98955056A patent/EP1024800B1/de not_active Expired - Lifetime
- 1998-10-23 AT AT98955056T patent/ATE222489T1/de active
- 1998-10-23 WO PCT/US1998/022383 patent/WO1999020263A1/en not_active Ceased
- 1998-10-23 AU AU11954/99A patent/AU1195499A/en not_active Abandoned
- 1998-10-23 DE DE69807349T patent/DE69807349T2/de not_active Expired - Lifetime
- 1998-10-23 ES ES98955056T patent/ES2181298T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1024800B1 (de) | 2002-08-21 |
| US5922775A (en) | 1999-07-13 |
| WO1999020263A1 (en) | 1999-04-29 |
| DE69807349T2 (de) | 2003-01-02 |
| AU1195499A (en) | 1999-05-10 |
| ES2181298T3 (es) | 2003-02-16 |
| EP1024800A1 (de) | 2000-08-09 |
| DE69807349D1 (de) | 2002-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE222489T1 (de) | Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren | |
| ATE300292T1 (de) | Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren | |
| DE69826695D1 (de) | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen | |
| ATE258796T1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
| DE69634900D1 (de) | Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis | |
| DE69127175D1 (de) | Antisens-Oligonukleotide zur Behandlung von Krebs | |
| DE69736745D1 (de) | Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe | |
| ATE347366T1 (de) | Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen | |
| DE69839586D1 (de) | Verwendung von ingenan derivaten zur herstellung eines medikaments zur krebsbekämpfung | |
| ATE411016T1 (de) | Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten | |
| ATE311853T1 (de) | Verwendung von krillenzymen zur behandlung von zahnbelag | |
| DE69532804D1 (de) | Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis | |
| ATE197670T1 (de) | Parenterales busulfan zur behandlung von malignen krankheiten | |
| ATE249233T1 (de) | Verwendung von gonadotropin releasing hormon analogen oder änlichen verbindungen zur herstellung von pharmazeutischen zubereitungen als zusatz für invasiver behandlung von karzinomen | |
| NO994330D0 (no) | Metode for behandling av en tumor | |
| NO932101D0 (no) | Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker | |
| ATE222119T1 (de) | Verwendung von erythropoietin zur behandlung von multiple myelom | |
| DE3854121D1 (de) | Arzneimittelzusammensetzungen zur behandlung von psoriasis. | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| DE59902666D1 (de) | Edelfosin zur behandlung von hirntumoren | |
| ATE181240T1 (de) | Verwendung von somatostatinanalogen zur behandlung von melanomen | |
| ES2110057T3 (es) | Composicion medicinal que contiene tcf-ii. | |
| DE59911556D1 (de) | Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor | |
| DE69732851D1 (de) | Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1024800 Country of ref document: EP |